Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

V-022

Supelco

Vigabatrin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C6H11NO2
Peso molecular:
129.16
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

InChI key

PJDFLNIOAUIZSL-UHFFFAOYSA-N

Gene Information

human ... ABAT(18)

Categorías relacionadas

General description

Vigabatrin is a newer antiepileptic sold as Sabril® in the US, Canada, Mexico and the United Kingdom and as Sabrilex in Denmark. The drug is used as an adjunctive treatment of complex partial seizures in adults and for infantile spasms in pediatric patients one month to two years of age. This certified Snap-N-Spike® Solution standard is suitable for use in LC/MS or GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Sabril is a registered trademark of Lundbeck LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 4

1 of 4

Rufinamide ≥98% (HPLC), powder

Sigma-Aldrich

R8404

Rufinamide

Lorazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-901

Lorazepam solution

α-Hydroxymidazolam solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-902

α-Hydroxymidazolam solution

Midazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-908

Midazolam solution

Lisa M Clayton et al.
Ophthalmology, 119(10), 2152-2160 (2012-08-03)
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL). Cross-sectional observational study.
Peter Weber et al.
Epilepsy & behavior : E&B, 24(1), 138-140 (2012-04-17)
We report the case of an adolescent girl who suffered from symptomatic refractory focal epilepsy after an arteria cerebri media insult 15 years prior to this report. Five weeks after initiation of an add-on therapy with vigabatrin, she was seizure
The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
O Heinzlef et al.
Revue neurologique, 168 Suppl 3, S62-S68 (2012-06-29)
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do
M Iu Dorofeeva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(6 Pt 2), 27-31 (2012-09-18)
Tuberous sclerosis complex is a multisystem genetic disorder. Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time. Onset usually occurs during childhood and up to one third of children with tuberous sclerosis
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico